Clinical Trial Update: The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial of Cleviprex in ventriculostomy patients requiring IV antihypertensive therapy was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Intracranial Hemorrhage
• Subarachnoid Hemorrhage

Drugs mentioned

• CLEVIPREX (clevidipine)

Snippet

Sponsor: Methodist Healthcare | Conditions: Hypertension, Intracranial Hemorrhage | Phase 4 | Status: WITHDRAWN